This event is the second in a new series of fireside chats covering career-related issues. Unlike the “Yale Career Panels: A Candid View of Professions” series that focuses on specific professions, this series is comprised of one hour conversations with one or two individuals about career related topics. The first fireside chat was held in December and covered “Managing Major Career Changes”

We are pleased to have two very accomplished individuals who have had deep and varied experiences as members of boards of directors of public and private companies, as well as non-profit organizations.

They will talk about how one gets on boards; what one can expect as a board member in terms of your commitment and role; the issues that are facing boards today; the differences in one’s board experience if it is a public, private, or non-profit organization; the dark sides of board membership (time commitment, personal liability); the board experience during major crises and events; the role of board committees; and the various myths (good and bad) about board membership.

The fireside chat will be broadcast via an interactive streaming video system. It will last for 45 minutes and will be followed by a 15 minute Q&A session.

**Time:** April 11, 2017 from 4:30 pm to 5:30 pm EST

**Webinar:** interactive streaming video

**Registration:** [https://yalecareerpanels-4-11-17.eventbrite.com](https://yalecareerpanels-4-11-17.eventbrite.com)

**Fireside Chat Interviewees:**

**Deborah Dunsire M.D.**  
CEO and President, Xtuit Pharmaceuticals

Deborah joined XTuit in 2017 as CEO and President to focus on new therapies to address fibrosis and cancer through targeting the microenvironment. She has over 25 years of experience developing and commercializing novel therapeutics across three continents.

She is the former President and CEO at FORUM Pharmaceuticals, which focused on therapies for Alzheimer’s disease, other dementias and schizophrenia. From 2005 to 2013 she was CEO and President of Millennium Pharmaceuticals, where she shepherded novel therapies through development and commercialization in the areas of cancer and inflammatory disorders. Under her leadership at Millennium, Velcade®, for multiple myeloma, transformed outcomes for patients. It became a multi-billion dollar product with Johnson & Johnson as the commercial partner outside of the US. In 2008, Takeda Pharmaceuticals of Japan acquired Millennium for $8.8 billion and, following the
acquisition, Deborah became the first woman to be appointed to the board of Takeda Pharmaceuticals in the company’s 236-year history. Prior to Millennium, Deborah spent 17 years at Novartis in South Africa, Switzerland and the US. For 11 years, she led the Novartis Oncology business in North America, developing and launching a number of transformational cancer therapies, notably Gleevec®, the first targeted cancer therapy, as well as Femara®, Zometa®, Sandostatin® and Exjade®. During her tenure at Novartis, the North American oncology business grew from $50 million to more than $2.2 billion.

Deborah is a member of the board of trustees for the Massachusetts General Physicians Organization, Northeastern University, and Boston’s Museum of Science. She serves on the Department of Chemistry Visiting Committee at MIT and on the MGH Research Advisory Council. She has served for many years as a board member of the Biotechnology Innovation Organization. She was also previously a long standing board member of Allergan until it was sold to Actavis.

Deborah was born in Zimbabwe and completed her medical training at the University of the Witwatersrand in Johannesburg, South Africa.

**Nancy Lurker**
**President and CEO, pSivida Corp.**

Nancy, a veteran in the biopharmaceutical industry, joined pSivida, a leader in the development of sustained release drug products, in September 2016 as President and Chief Executive Officer and is a member of the company’s Board of Directors. pSivida is a publicly traded company. She has more than 30 years of experience in the pharmaceutical and pharmaceutical services industries.

Prior to joining pSivida, Nancy was President and CEO at PDI where she grew revenues and market share substantially in a turbulent and rapidly changing market. During her tenure, PDI launched and commercialized hundreds of pharmaceutical drugs, devices, OTC and diagnostic tests in collaboration with its business partners through its 1100 sales representatives. Prior to joining PDI, she was Senior Vice President and Chief Marketing Officer for Novartis Pharmaceuticals Corporation (the US subsidiary of Novartis AG), where she oversaw a product portfolio in multiple therapeutic areas, including cardiovascular, CNS, respiratory and anti-infectives, representing multi-billion dollars in annual sales.

Nancy was also President and CEO of ImpactRx, a private equity backed market research firm servicing the biopharmaceutical industry. Prior to ImpactRx she was Group Vice President – Global Primary Care Products for Pharmacia Corporation, and a member of Pharmacia’s US Executive Management Committee. She began her career at Bristol Myers Squibb, where she quickly rose from Senior Sales Representative to Senior Director of Worldwide Cardiovascular Franchise Management where she oversaw the global launch of Plavix, among many other successful drug launches.
Nancy serves as Chair of X4 Pharmaceuticals, a private oncology company; is on the Board of Cancer Treatment Centers of America, a multi-billion dollar private cancer treatment hospital system; and is a member of the Novo Advisory Group, which advises Novo A/S on their large investments.

Nancy graduated magna cum laude with a BS in biology from Seattle Pacific University, and holds an MBA from the University of Evansville (Evansville, IN).

**Moderator and Organizer:**

**Peter Young**
**President and Managing Director, Young & Partners**

Peter Young is President and a Managing Director of Young & Partners, a boutique investment banking firm focused on the life science and chemical industries. He manages the firm and is actively involved in client transactions and financings. Under his leadership, Young & Partners has established and maintained its position as a highly regarded firm serving the M&A, restructuring and financing needs of clients worldwide.

Mr. Young received a BA in Economics from Yale, an MS in Accounting from NYA, and MBA from Harvard Business School where he graduated with Highest Distinction as a Baker Scholar. He serves on a number of boards of directors, both corporate and non-profit.

**Upcoming Events**

Yale Career Panels: A Candid View of the Real Estate Profession will be held on April 4 from 4:30 pm EST to 5:30 pm EST. To register, go to [https://yalecareerpanels-4-4-17.eventbrite.com](https://yalecareerpanels-4-4-17.eventbrite.com)

**The Series Sponsors**

This series is jointly supported by various organizations at Yale University and Yale Alumni organizations, including Yale Office for Career Strategies, the Association of Yale Alumni (AYA), the Yale School of Management, Students and Alumni of Yale (STAY), the Junior Class Council (JCC), the Yale Alumni Association of New York (YAANY), the Asian American Cultural Center, SOM Alumni-New York Chapter, and the Association of Asian American Yale Alumni (AAAYA).